All In Biotech

Drug Trial Radar · NCT04752826

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 as a Single Agent and in Combination With Pembrolizumab (MK-3475-D20) in Subjects With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Jan 25, 2021

Primary completion

Jan 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
BioInvent International ABIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Feb 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1808 * what is maximum tolerated or administrated dose * to determine recommended dose for further clinical trials. Participants will receive infusions of with BI-1808 as a single agent, BI-1808 in combination with pembrolizumab and BI-1808 in combination with pembrolizumab and paclitaxel every 3 weeks. For the purpose of this study, subjects with advanced malignancies includes subjects with advanced solid tumors and subjects with T-cell lymphoma (TCL),

Conditions

  • Advanced Malignancies
  • Ovarian Cancer
  • T-cell Lymphoma
  • Melanoma

Interventions

  • BI-1808Drug

    BI-1808 administered as a flat-dose IV infusion once every 3 weeks

  • Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for InjectionDrug

    Pembrolizumab administered as a flat-dose IV infusion once every 3 weeks.

  • Paclitaxel 80 mg/m2 weeklyDrug

    Paclitaxel administered as a flat-dose IV infusion weekly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of adverse events (AEs)Time frame: From the start of the study treatment for up to 2 years and 90 days.
  2. Identify DLTs, determine the maximum tolerated dose and select a recommended Phase 2 dose (RP2D) of BI-1808, given via intravenous (IV) infusion, as a single agent (Phase 1, Part A), and in combination with pembrolizumab (Phase 1, Part B)Time frame: Up to 104 weeks (2 years)
  3. Occurrence of serious adverse events (SAEs)Time frame: Up to 104 weeks (2 years)
  4. To identify the recommended Phase 2 dose (RP2D) of BI-1808,Time frame: up to 104 weeks (2 years)

Locations

25 sites in 7 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Herlev Hospital

    Herlev, Denmark · Recruiting

  • PRA Health Sciences - Hungary

    Budapest, Hungary · Active not recruiting

  • Magyar Honvédség-Egészségügyi Központ

    Budapest, Hungary · Recruiting

  • Debreceni Egyetem Klinikai Központ

    Debrecen, Hungary · Withdrawn

  • Byudzhetnoye Uchrezhdeniye Zdravookhraneniya Omskoy Oblasti - Klinicheskiy Onkologicheskiy Dispanser

    Omsk, Russia · Terminated

  • National Medical Research Center VA Almazov

    Saint Petersburg, Russia · Withdrawn

  • N.N. Petrov National Medical Research Center of Oncology

    Saint Petersburg, Russia · Withdrawn

  • Institut Catala d'oncologia. Hospital Duran I Reynals

    Barcelona, Spain · Not yet recruiting

  • Hospital Universitario Puerta de Hierro-Majadahonda, Madrid,

    Madrid, Spain · Not yet recruiting

  • START Madrid - Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Sahlgrenska University Hospital

    Gothenburg, Sweden · Recruiting

  • Skanes University Hospital

    Lund, Sweden · Recruiting

  • Karolinska University Hospital, Solna

    Stockholm, Sweden · Recruiting

  • University Hospital Birmingham

    Birmingham, United Kingdom · Recruiting

  • University Hospitals of Leicester NHS Trust

    Leicester, United Kingdom · Recruiting

  • Guy's and Saint Thomas' NHS Foundation Trust

    London, United Kingdom · Recruiting

  • Sarah Cannon Research Institute UK

    London, United Kingdom · Recruiting

  • The Royal Marsden Hospital NHS Foundation Trust

    London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

  • Southampton General Hospital

    Southampton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.